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Transporter associated with antigen processing 2 (Tap-2) is responsible for ATP-dependent transport of
peptides from the cytosol to the endoplasmic reticulum, where peptides bind to newly synthesized human
leukocyte antigen (HLA) class I molecules, which are essential for cellular immune responses. Epstein-Barr
virus (EBV) latent membrane protein 1 (LMP-1) has been shown to induce the expression of Tap-2. In this
study, the induction of endogenous Tap-2 by LMP-1 is shown to be associated with and requires the expression
of interferon regulatory factor 7 (IRF-7). In DG75 Burkitt’s lymphoma (BL) cells, in which LMP-1 induces the
expression of IRF-7, LMP-1 induced endogenous Tap-2, and ectopic expression of IRF-7 could enhance the
induction. In Akata BL cells, in which LMP-1 could not induce IRF-7, LMP-1 could not induce Tap-2. Addition
of IRF-7, which complements the defect in Akata cells, could stimulate the expression of Tap-2. Furthermore,
LMP-1 and IRF-7A but not other IRF-7 splicing variants could activate endogenous Tap-2. A Tap-2 promoter
reporter construct could be activated by the overexpression of IRF-7A. The activation could be specifically
enhanced by LMP-1 and was dependent on an intact interferon-stimulated response element (ISRE) present
in the Tap-2 promoter. Also, IRF-7 can bind to the Tap-2 promoter under physiological conditions in vivo, as
shown by formaldehyde cross-linking, as well as to the Tap-2 ISRE in vitro, as shown by gel mobility shift
assays. Furthermore, LMP-1 facilitates the phosphorylation and nuclear translocation of IRF-7. These data
point to the role of IRF-7 as a secondary mediator of LMP-1-activated signal transduction for Tap-2 as follows:
LMP-1 stimulates the expression of IRF-7 and facilitates its phosphorylation and nuclear translocation, and
then the activated IRF-7 mediates the activation of the cellular Tap-2 gene. The induction of Tap-2 by IRF-7
and LMP-1 may have an important implication for the immune response to EBV and its persistence in vivo.
Infection by Epstein-Barr virus (EBV) may contribute to the
development of malignant diseases such as Hodgkin’s disease,
Burkitt’s lymphoma (BL), nasopharyngeal carcinoma, and
posttransplant lymphoproliferative diseases (reviewed in refer-
ences 20, 37, 41, and 44). In vitro, EBV efficiently infects and
immortalizes primary B lymphocytes (reviewed in references
19 and 44), and latent membrane protein 1 (LMP-1) expres-
sion is required for this immortalization process (18).
LMP-1 is an integral membrane protein with six membrane-
spanning domains with a long C-terminal domain, which is
located in the cytoplasm (19, 23). LMP-1 acts as a constitu-
tively active receptor-like molecule, which does not need the
binding of a ligand (14). The six transmembrane domains me-
diate oligomerization of LMP-1 molecules in the plasma mem-
brane, a prerequisite for LMP-1 function (11, 14). So far, two
domains in the C terminus of LMP-1 have been shown to
initiate signaling processes: C-terminal activator region 1
(CTAR-1, amino acids 194 to 231) and region 2 (CTAR-2,
amino acids 332 to 386) (16, 29).
LMP-1 can induce a variety of cellular genes that enhance
cell survival and adhesive and invasive potential (12, 27, 59, 60,
64). Interestingly, LMP-1 can stimulate the expression of the
transporter associated with antigen processing 2 (TAP-2) gene
(46). Tap-2 is involved in the ATP-dependent transport of
peptides from the cytosol to the endoplasmic reticulum, where
peptides bind to newly synthesized HLA class I molecules,
which are essential for cellular immune responses (for a re-
view, see references 3 and 57).
Tap-2 appears to be involved in some human diseases.
Mutation of Tap-2 may cause defective precessing of HLA I,
leading to primary immunodeficiency (55). Tap-2 mutation
has been associated with familial bronchiectasis and with
susceptibility to Sjo¨gren’s syndrome (10, 21). Tap-2B may
increase the risk for nickel allergy (52). Tap-2 polymorphism
may also be involved in inflammatory bowl disease (15).
Understanding the regulation of Tap-2 is essential to elucidate
its role in the pathogenesis of these as well as EBV-associated
diseases.
The mechanism leading to upregulation of Tap-2 by LMP-1
is currently unknown. Previous results suggest that LMP-1
stimulates the expression of interferon-regulatory factor 7
(IRF-7) (66). IRF-7 was first cloned by its binding activity to
the EBV BamHI Q promoter (Qp), used in latent EBV infec-
tion for transcription of EBNA-1, and has subsequently proven
to be a negative regulator of Qp (65–67). IRF-7 belongs to the
IRF family, a group of transcription factors with multiple func-
tions (reviewed in reference 33). The hallmark of this family is
the conserved N-terminal DNA-binding domain which has the
potential to bind to interferon-stimulated response elements
(ISREs) and regulate the activity of promoters containing
ISREs. Because there is a putative ISRE in the Tap-2 pro-
moter region, whether IRF-7 is involved in regulation of the
Tap-2 gene was investigated. In this paper, we report that
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IRF-7 is a secondary mediator of LMP-1-triggered signal
transduction for activation of the Tap-2 gene.
MATERIALS AND METHODS
Cell culture. DG75 is an EBV-negative BL cell line (4); BL30 and BL41 are
EBV-negative BL lines with EBV-infected counterparts generated by in vitro
infection with the P3HR1 strain (BL30-P3HR1 and BL41-P3HR1) or the B95-8
strain (BL30-B95-8 and BL41-B95-8) of EBV (5). Akata is an EBV-positive type
I BL cell line, and Jijoye is an EBV-positive type III BL cell line (42, 53). Sav-I
and Sav-III are paired EBV-positive BL lines that differ only in their latent
infection state (35, 46). X50-7 and B958/CBC are EBV-positive lymphoblastoid
cell lines. FaDuHyg is an EBV-negative epithelial cell line (43). T2 is a lympho-
blastic cell line with a deletion of the Tap-2 genomic sequence (47, 48). All cell
lines were maintained in RPMI 1640 plus 10% fetal bovine serum.
Plasmids and antibodies. A PCR fragment containing the Tap-2 promoter region,
starting at its ISRE and ending at the first coding sequence, was cloned into pBS-
CAT (13). The PCR fragment corresponded to nucleotides (nt) 115644 to 116217 of
a published sequence (GenBank accession no. X87344) (2). The cloned promoter
was identical to the published sequence except for missing 2 T’s within a stretch of
T’s (nt 115965 to 115985). Such a sequence has been found in several PCR clones.
We do not know whether this variation was due to a PCR error or a polymorphism.
However, this sequence variation seems to play no important role in Tap-2 promoter
activity, because results from reporter assays were in agreement with the levels of
endogenous Tap-2 RNA (see Fig. 3 to 5). Mutations in the ISRE region (nt 115649
to 115662) were made by PCR with a mutated primer, and mutations were con-
firmed by sequencing analysis (see Fig. 3A). IRF-7 expression plasmids and IRF-7
antibody have been described (67). pcDNA/CD4 is a human CD4 expression plas-
mid (gift of Jenny Ting). IRF-7DN (amino acids [aa] 1 to 12 and 103 to 503) is a gift
from Tom Maniatis (61). Epidermal growth factor promoter (EGFP)-IRF-7 was
cloned by inserting the full-length IRF-7A into the BglII site of the pEGFP-c1 vector
(Clontech). The b-galactosidase expression plasmid pCMVb(6177-1) was purchased
from Clontech. LMP-1 expression plasmid pcLMP-1 was a gift from Tomakazu
Yoshizaki. The mutant LMP-1 plasmids LMP1-231 and LMPD231-387 were gifts
from Nancy Raab-Traub (28). The interferon consensus sequence binding protein
(ICSBP) and IRF-3 expression plasmids were cloned in the expression plasmid
pcDNA3. The IRF-1 (C-20) and IRF-2 (C-19) antibodies were purchased from
Santa Cruz Biotechnology, Inc. LMP-1 monoclonal antibody CS1-4 was purchased
from Dako. Antitubulin antibody was from Sigma. Tap-2 antibody has been de-
scribed (58). The IRF-7 C-terminus-specific antiserum was generated by injection of
glutathione-S-transferase (GST)-IRF-7B fusion protein (aa 218 to 474) into a rabbit.
This IRF-7 antiserum was used only for the experiment shown in Fig. 2C, and the
full-length IRF-7B antiserum was used in all other applications (67).
Western blot analysis with enhanced chemiluminescence. Separation of pro-
teins on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) followed standard methods. After the proteins were transferred to a
nitrocellulose or Immobilon membrane, the membrane was blocked with 5%
nonfat dry milk in TBST (50 mM Tris [pH 7.5], 200 mM NaCl, 0.05% Tween 20)
at room temperature for 10 min. It was then washed briefly with water and
incubated with primary antibody in 5% milk in TBST for 1 to 2 h at room
temperature or overnight at 4°C. After being washed with TBST three times for
10 min each, the membrane was incubated with the secondary antibody at room
temperature for 1 h. It was then washed three times with TBST as before, treated
with ECL (Amersham) or SuperSignal (Pierce) detection reagents, and exposed
to Kodak XAR-5 film.
Transient transfection, enzyme assays, and isolation of transfected cells. Cells
(107) in 0.5 ml of medium were transfected with the use of a Bio-Rad Gene
Pulser (320 V and 925 mF). Two days after transfection, cells were collected for
chloramphenicol acetyltransferase (CAT) assay or for isolation of transfected
cells. The CAT and b-galactosidase assays were performed essentially as de-
scribed (22). The CAT assay results were analyzed on a Molecular Dynamics
PhosphorImager.
For isolation of transfected cells, cells were collected after transfection, and
enrichment for CD4-positive cells was performed with the use of anti-CD4
antibody conjugated to magnetic beads according to the manufacturer’s recom-
mendation (Dynal, Inc.). The isolated cells were used for the extraction of total
RNA.
RNA extraction and RPA. Total RNA was isolated from cells with the use of
RNease total RNA isolation kit (Qiagen). The RNase protection assay (RPA)
was performed with total RNA with the use of either the Lysate RNase protec-
tion kit (US Biochemicals, Inc.) (Fig. 1) or the RNase protection kit II (Ambion
Inc; all other figures). The hybridization temperature was 37°C for Fig. 1 and
45°C for the rest of the figures. The glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) probe was supplied by US Biochemicals, Inc. The Tap-2 RPA probe
was made by PCR with the primers 59-GCTCTAGATAATACGACTCACTAT
AGGGCGACAGACCCAAGCTTGGTACCGAGCTCGGATCCCGCTCTCA
GGGAGACAGTCA-39 and 59-GCTCTAGACTGGACCTCCCTGCTGCTGG
TGGAC-39. The PCR product contains a T7 promoter, a spacer region, and the
Tap-2 first exon sequence (complementary to nt 116227 to 116458 of the se-
quence published in GenBank [no. X87344]). The PCR product was purified and
used directly for synthesis of RNA probe.
EMSA. For the electrophoretic mobility shift assay (EMSA), the Tap-2 ISRE-
containing fragment was obtained by annealing two oligonucleotides, 59-GATC
GGAAGCGAAAGCGAAAGCTGCCC-39 and its complement, with GATC at
the 59 end. The mutated ISRE probe was made exactly the same way with
mutated oligonucleotides, as shown in Fig. 3A. The DNA probes were generated
by filling in any single-stranded overhang with Klenow enzyme. EMSA was
performed essentially as described (65, 67). In vitro-translated reticulate lysates
(5 ml) were incubated with 20,000 to 50,000 cpm of labeled probe in a volume of
12.5 ml containing 20 mM HEPES (pH 7.9), 1 mM MgCl2, 0.1 mM EGTA, 0.5
mM dithiothreitol, 320 mg of poly(dI-dC):poly(dI-dC), and 4% Ficoll-400 for 20
min at room temperature. The samples were separated on a preelectrophoresed
4.8% polyacrylamide gel in 20 mM Tris-borate-EDTA (TBE) buffer. After elec-
trophoresis, gels were dried, followed by autoradiography. When antiserum was
needed, 1 ml was added to the reaction mixture. The consensus ISRE oligonu-
cleotide has been described (67). AP-1 binding site competitor was purchased
from Promega.
In vitro transcription and translation. The proteins were made with the TNT
coupled transcription and translation kit (Promega) essentially according to the
manufacturer’s instructions. Wheat germ lysate was used with the plasmid
pcDNA-IRF-7A, and rabbit reticulocyte lysate was used with the plasmid
pcDNA-IRF-7C.1.
Analysis of DNA-binding activity by in vivo formaldehyde cross-linking. The
cross-linking method is based on a previous publication (36). Cells were fixed
with 1/10 volume of 11% formaldehyde solution in 0.1 M NaCl–1 mM EDTA–0.5
mM EGTA–50 mM HEPES (pH 8.0) for 1 h at 4°C. The cross-linking reaction
was stopped by adding glycine to 0.125 M. The cells were washed and sonicated,
and the cell debris was removed by centrifugation at 15,000 3 g for 10 min as
described (36). The cell lysates were cleared first by incubating with protein
G-agarose beads and preimmune serum. Then immunoprecipitations were per-
formed with preimmune or immune serum specific for the C-terminal region of
IRF-7 at 4°C overnight. Immunoprecipitates were collected by protein G-agarose
beads and washed three times for 10 min each in 13 phosphate-buffered saline
(PBS) solution plus phenylmethylsulfonyl fluoride (PMSF) and another three
times for 10 min each in Tris-EDTA (TE) buffer. Finally, the pellets were
digested at 65°C overnight in 100 ml of TE plus 0.5% SDS and proteinase K (500
mg/ml). After phenol-chloroform extraction, the DNA was precipitated with
glycogen as the carrier. The isolated DNA was used as the template for ampli-
fication of the Tap-2-specific region with primers 59-GAGTTCGGAAGGCCT
TGG-39 (corresponding to nt 115623 to 115640) and 59-GAAGCAGGAGCGT
GGAGT-39 (complementary to nt 115856 to 115873) (2). The PCR products
were separated in a 1.5% agarose gel, transferred to a nylon membrane, and
hybridized to labeled Tap-2 promoter probe (nt 115644 to 116217), which was
synthesized with random primer and Klenow enzyme by the use of standard
methods (49).
Phosphorylation analysis and immunoprecipitation. 293T cells were cotrans-
fected with expression plasmids for IRF-7A and LMP-1 with the use of Effectene
(Qiagen). Cells were then labeled with [32P]orthophosphate for 4 h, washed once
with 13 TBS, and lysed in a buffer containing 0.5% NP-40, 50 mM Tris-Cl (pH
7.5), 150 mM NaCl, 5 mM EDTA, 100 mM NaF, 1 mM sodium orthovanadate,
and 1 mM PMSF. Cell lysates were precleared with preimmune serum and
protein G-agarose beads under gentle agitation at 4°C for 30 min. The anti-
IRF-7 antiserum and protein G-agarose were then added, and lysates were
incubated overnight at 4°C. The beads were washed three times with 1 ml of
immunoprecipitation washing buffer, resuspended in 50 ml of SDS-PAGE sam-
ple loading buffer, and boiled for 5 min. Samples were resolved by electrophore-
sis on an SDS-polyacrylamide gel and transferred onto an Immobilon membrane.
The membrane was dried and autoradiographed. After autoradiography, the
membrane was rehydrated with 100% methanol for 30 s and used for Western
blotting to visualize the total amount of IRF-7.
Immunofluorescence. 293T cells grown on chamber slides (Lab-TeK) were
transfected with plasmids. Twenty-four hours after transfection, the cells were
fixed by 60% acetone, stained with DAPI (49,69-diamidino-2-phenylindole, 1
mg/ml) in PBS, and mounted with 60% glycerol in PBS. Samples were examined
with a Zeiss Axioskope.
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RESULTS
Expression of Tap-2 is associated with IRF-7 and LMP-1. It
has been shown recently that EBV LMP-1 protein stimulates
the expression of IRF-7 (66). Since LMP-1 can induce a variety
of genes, whether IRF-7 is a secondary mediator for some of
those induced genes was examined. Tap-2 was especially inter-
esting not only because it is induced by LMP-1, but also be-
cause of the putative ISRE in the Tap-2 promoter region (2).
With the use of RPA and a specific probe for Tap-2, whether
expression of Tap-2 RNA is associated with expression of
IRF-7 and LMP-1 was addressed. Sav-I and Sav-III are sister
Burkitt’s lymphoma lines both derived from a single parental
cell line. The paired lines differ only in their types of latency.
Sav-III cells, which express LMP-1, have a higher IRF-7 level
than Sav-I cells, which do not express LMP-1 (Fig. 1B) (67).
Another pair of cell lines, BL30-P3HR1 and BL30-B95-8, were
established by infecting the EBV-negative BL30 line with
P3HR1 or B95-8 virus, respectively. BL30-P3HR1 expresses
very low levels of LMP-1 and IRF-7, whereas BL30-B95-8 cells
express high levels of LMP-1 and IRF-7A (Fig. 1B) (66). In
both lines, the level of Tap-2 RNA correlates with expression
of IRF-7 and LMP-1 (Fig. 1A). Similar results were obtained
with another set of paired cell lines, BL41-P3HR1 and BL41-
B95-8. Also, Akata cells (low endogenous IRF-7, no LMP-1)
have lower Tap-2 RNA levels than Jijoye cells (high IRF-7 and
LMP-1) (data not shown). Finally, in EBV-negative BJAB and
BL41 cell lines expressing LMP-1, both Tap-2 and IRF-7 pro-
tein levels were increased (data not shown) (46, 66). All these
data suggest that Tap-2 expression is associated with expres-
sion of IRF-7 and LMP-1.
IRF-7 binds to Tap-2 promoter in vitro and in vivo. A
putative ISRE sequence has been identified based on sequence
homology in the Tap-2 promoter region (2). Because IRFs
have potential to bind to ISRE, whether IRF-7 can bind to the
putative Tap-2 ISRE was tested by EMSA. IRF-7 was in vitro
translated, and lysate was used for EMSA with labeled Tap-2
ISRE as a probe. As shown in Fig. 2, specific bands appeared
when IRF-7A was used for EMSA (lanes 3 to 10). These bands
were specific because they disappeared with an excess of un-
labeled competitors, such as Tap-2 ISRE and consensus ISRE
from the interferon-stimulated gene (ISG) 15 promoter (lanes
4 and 6), but mutated Tap-2 ISRE or nonspecific competitor,
such as AP-1 binding site, had no effect (lanes 5 and 7), and
DNA-binding activity was not affected when preimmune serum
or nonrelevant antibody (anti-IRF-2) was used (lanes 8 and
10); however, specific IRF-7 antibody could block and super-
shift the IRF-7A–DNA complex (lane 9). Furthermore, IRF-
7C, which has only the N-terminal 164 aa (Fig. 3B), can spe-
cifically bind to the Tap-2 ISRE sequence (lanes 11 to 17),
indicating that the DNA-binding domain of IRF-7 to Tap-2
ISRE is localized in the N-terminal region, as expected (67).
All previous attempts to identify the IRF-7–Tap-2 ISRE
complex in cell lysates by EMSA have failed. Interestingly, in
these experiments, IRF-2 from the same cell lysates could
clearly bind to the Tap-2 ISRE (data not shown), which also
confirms the authenticity of the Tap-2 ISRE.
In order to test whether physiological levels of IRF-7 can
bind to the Tap-2 promoter in vivo, X50-7 cells, a type III EBV
latency cell line with high levels of IRF-7 and LMP-1, were
fixed with formaldehyde, and IRF-7-DNA complexes were iso-
lated by immunoprecipitation with IRF-7 antiserum. The DNA
recovered from the immunoprecipitates was used as the tem-
plate for PCR amplification of the Tap-2 promoter region
containing the ISRE. The authenticity of the PCR products
was verified by Southern blot analysis with the Tap-2 promoter
sequence as a probe (see Materials and Methods for details).
As shown in Fig. 2B, IRF-7-specific antiserum could specifi-
cally precipitate the IRF-7 protein–Tap-2 promoter complex
(lane 2). However, preimmune serum did not bring down any
Tap-2 DNA (lane 1). Similar results were also obtained with
another type III latency cell line, Jijoye (data not shown). From
these data, we conclude that IRF-7 is able to bind to the Tap-2
promoter under physiological conditions in vivo.
IRF-7A activates Tap-2 promoter constructs. The effect of
IRF-7 on the promoter activity of the Tap-2 gene was studied
using Tap-2 promoter constructs in transient-transfection assays.
The Akata cell line was chosen because of its low endogenous
expression of IRF-7, and LMP-1 cannot induce IRF-7 in this
particular cell line. A Tap-2 promoter construct containing the
ISRE sequence, Tap-2-CAT, was cloned according to the pub-
lished sequence (2). Cotransfection of an IRF-1 or IRF-7-expres-
sion plasmid with Tap-2-CAT resulted in activation of the Tap-2
FIG. 1. Tap-2 RNA is associated with IRF-7 and LMP-1. (A) Tap-2
RNA in various paired cell lines. Tap-2 and GAPDH probes were labeled
with [a-32P]UTP and used for RPA. Lanes 1 and 2, undigested Tap-2 and
GAPDH probes; lane 3, yeast tRNA; lanes 4 and 5, RNAs from Sav-I and
Sav-III cells, respectively; lanes 6 and 7, RNAs from BL30-P3HR1 and
BL30-B95-8 cells, respectively. (B) IRF-7 and LMP-1 levels in cell lysates
from various cell lines. Equal amounts of protein lysates from cell lines
were electrophoresed in SDS–8% PAGE. Western blotting with IRF-7 or
LMP-1 and tubulin antibodies was performed.
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promoter construct (Fig. 3C, columns 2 and 6). However, IRF-2,
IRF-3, ICSBP, IRF-7B (which is lacking 29 aa in the middle of
the protein), and IRF-7DN (aa 1 to 12 and 103 to 503), which
lacks the N-terminal DNA-binding domain of IRF-7 (Fig. 3B)
(61, 67), could not activate the Tap-2 promoter construct. Nor
could IRF-7C, which lacks the C-terminal domain of IRF-7 by
alternative splicing (67), activate the Tap-2 promoter construct
(Fig. 3B and data not shown). The activation of the Tap-2 pro-
moter by IRF-7 and IRF-1 was only observed with the intact
ISRE sequence; IRF-7 and IRF-1 failed to activate the Tap-2
promoter construct with ISRE mutations (mTap2-CAT) that
abolish IRF-7 binding (Fig. 2 and 3D). The Tap-2 ISRE is ap-
parently not essential for the constitutive activity of the Tap-2
promoter, because the ISRE mutations only reduced the consti-
tutive activity slightly (data not shown). These data suggest that
both N- and C-terminal domains of IRF-7 are required for trans-
activation of the Tap-2 promoter and that binding of IRF-7 to the
Tap-2 promoter is essential for its activation.
LMP-1 enhances the activation of Tap-2 promoter construct by
IRF-7. Since both IRF-7 and LMP-1 are associated with high
levels of Tap-2 expression (Fig. 1), whether LMP-1 can enhance
the activation of the Tap-2 promoter by IRF-7 was tested in
Akata cells. LMP-1 alone could not activate the Tap-2 construct
(Fig. 3C, column 9); however, LMP-1 plus IRF-7 could enhance
the activation of the Tap-2 reporter construct (column 14). The
enhancement was not due to the increase in IRF-7 expression
(see Fig. 4C). LMP-1 plus IRF-7B may also activate TAP-2 (lane
15). LMP-1 plus other IRFs or IRF-7DN did not activate the
Tap-2 promoter further (columns 10 to 13 and 16). Once again,
the intact ISRE was essential for Tap-2 activation, because ISRE
mutations abolished the activation by IRF-7 and LMP-1 (Fig.
3D). These data suggest that LMP-1 specifically enhances the
activation of the Tap-2 promoter by IRF-7.
IRF-7 is involved in the induction of endogenous Tap-2 RNA
by LMP-1. Whether IRF-7 is involved in the regulation of the
endogenous Tap-2 gene was examined. An EBV-negative Bur-
kitt’s lymphoma cell line, DG75, was chosen because of transfec-
FIG. 2. IRF-7 binds to Tap-2 promoter. (A) IRF-7 binds to Tap-2 ISRE in vitro. EMSA was performed with the Tap-2 ISRE probe labeled
with [a-32P]dCTP. Unlabeled competitors were all added at a 100-fold molar excess over the labeled probe. Lanes 1 and 11, free probe; lane 2,
wheat germ lysate containing in vitro-translated protein from plasmid pcDNA3; lanes 3 to 10, wheat germ lysate containing in vitro-translated
protein from pcDNA-IRF-7A. The Tap-2 ISRE and the ISRE sequence from the ISG15 gene (ISG15 ISRE) were used as unlabeled competitors
in lanes 4 and 6, and the mutated ISRE (mTap2-ISRE) and AP-1 binding site were used for lanes 5 and 7. Preimmune, preimmune serum for
IRF-7B protein. Preimmune serum was used for lane 8, and IRF-7 antiserum was used for lane 9. Nonrelevant rabbit polyclonal antibody (Ab)
against IRF-2 (Santa Cruz) was used for lane 10. Lane 12, reticulocyte lysates containing in vitro-translated proteins from plasmid pcDNA3; lanes
13 to 17, reticulocyte lysates containing in vitro-translated protein from plasmid pcDNA-IRF-7C.1; Tap-2 ISRE, mTap2-ISRE, ISG15 ISRE, and
AP-1 unlabeled competitors were used in lanes 14 to 17, respectively. n.s., nonspecific. (B) IRF-7 binds to Tap-2 in vivo. X50-7 cells were treated
with formaldehyde to cross-link proteins bound to DNA. Cross-linked complexes were immunoprecipitated with preimmune (lane 1) and immune
(lane 2) antisera to IRF-7. After reversal of the cross-linking, the DNA was then amplified by Tap-2 promoter-specific primers. The PCR products
were separated on an agarose gel and analyzed by Southern blot hybridization with the 32P-labeled Tap-2 promoter fragment containing the ISRE
as the probe after transfer to a nylon membrane.
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tion efficiency and because LMP-1 can stimulate the expression of
IRF-7 in this line (66). Expression plasmids were transfected into
the cells along with a CD4 expression plasmid. Two days after
transfection, the transfected cells were enriched by magnetic
beads conjugated with anti-CD4 antibody (see Materials and
Methods for details). Total RNA was isolated, and RPA was
employed with specific probes. As shown in Fig. 4, LMP-1 in-
creases Tap-2 RNA about twofold (lane 5). IRF-7A alone has
minimal effect on the Tap-2 RNA (lane 6). However, LMP-1 and
IRF-7 together increased Tap-2 RNA levels almost fourfold (lane
7). The identity of the protected band as Tap-2 RNA was con-
firmed by testing RNA from the T-2 cell line, which has a genomic
deletion in the Tap-2 gene (lane 3). Tap-2 expression was not
increased further by LMP-1 plus IRF-7C, IRF-7DN (Fig. 4, lanes
8 and 9), or IRF-7B (data not shown). IRF-7DN was able to
repress the promoter activity of the beta interferon (IFN-b) gene
after viral infection (61). IRF-7DN may also repress LMP-1-
induced Tap-2 expression (Fig. 4, compare lane 4 to lane 9).
These data suggest that IRF-7 is involved in the activation of
Tap-2.
IRF-7 and LMP-1 coactivate the endogenous Tap-2 gene.
Whether IRF-7 is involved in the activation of endogenous
Tap-2 was further examined in Akata cells, in which LMP-1
cannot induce IRF-7 RNA (66). If LMP-1 activates Tap-2
through IRF-7, then LMP-1 alone would have no effect, but
IRF-7 plus LMP-1 would activate the Tap-2 gene in this par-
ticular cell line. Expression plasmids were transfected into the
cells along with a CD4 expression plasmid. Total RNA was
isolated from CD4-positive cells, and RPA was employed with
specific probes. As shown in Fig. 5, overexpression of neither
FIG. 3. Activation of Tap-2 promoter reporter construct by IRF-7. (A) Schematic diagrams of Tap-2 reporter constructs. Top line, Tap-2
genomic region; open rectangle, ISRE. A 573-bp fragment from the Tap-2 promoter region was cloned; the ISRE sequence and mutations are
shown. (B) Schematic diagrams of various IRF-7 expression plasmids. IRF-7A, -7B, and -7C are splicing variants of IRF-7. IRF-7DN lacks the
DNA-binding domain. (C) Activation of Tap-2 reporter construct by IRF-7 in B cells. Akata cells were transfected with the reporter construct
Tap2-CAT together with vector pcDNA-3 (column 1) or expression plasmids for IRF-1 (column 2), IRF-2 (column 3), IRF-3 (column 4), ICSBP
(column 5), IRF-7A (column 6), IRF-7B (column 7), IRF-7DN (column 8), or LMP-1 (column 9). Columns 10 to 16, pcLMP-1 was cotransfected
with IRF-1, IRF-2, IRF-3, ICSBP, IRF-7A, IRF-7B, and IRF-7DN, respectively. (D) Mutations in ISRE abolish activation by IRF-7. Akata cells
were transfected with the reporter construct mTap2-CAT and pcDNA-3 (column 1) or IRF-7A (column 2) or IRF-7A plus pcLMP-1 (column 3)
or IRF-1 expression plasmid (column 4). CAT assay results were normalized to b-galactosidase activity. CAT activity is expressed relative to the
vector control. Standard deviations are shown.
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LMP-1 nor IRF-7 alone could stimulate the expression of
Tap-2 in Akata cells (lanes 3 and 4). However, LMP-1 and
IRF-7 together increased the Tap-2 RNA level 2.8-fold (lane
5). As expected, Western blot analysis showed that the level of
Tap-2 protein was also increased by expression of LMP-1 and
IRF-7 (Fig. 5C). These data suggest that LMP-1 and IRF-7
coactivate endogenous Tap-2.
Because IFN activates Tap-1 and HLA class I genes and
because the entire class I system, including Tap-2, is usually
upregulated simultaneously (reviewed in references 32, 54, and
63), we tested whether IFN-a can activate Tap-2 in Akata cells.
The endogenous Tap-2 RNA was increased 3.5-fold upon IFN
treatment (Fig. 5, lanes 6 and 7). If the efficiency of transfec-
tion and selection of transfected cells are considered, LMP-1
plus IRF-7 can induce Tap-2 to a level similar to that induced
by IFN.
IRF-7A and full-length LMP-1 are required for the activa-
tion of Tap-2. The CAT assay results suggested that IRF-7A
but not other IRF-7 splicing variants is an activator of the
Tap-2 promoter in Akata cells (Fig. 3). Whether other forms of
IRF-7 are capable of activating endogenous Tap-2 was exam-
ined by transfection with various forms of IRF-7 along with
LMP-1 and monitoring the endogenous Tap-2 levels in Akata
cells. As shown in Fig. 6 (lanes 1 to 8), only IRF-7A plus
FIG. 4. IRF-7 is involved in the activation of endogenous Tap-2
RNA. (A) RPA was performed with Tap-2 and GAPDH probes. Lane
1, undigested Tap-2 probe; lane 2, yeast RNA; lane 3, RNA from T-2
cell line. Lanes 4 to 9, RNAs from transfected and selected DG75 cells;
lane 4, pcDNA3; lane 5, pcLMP-1; lane 6, pcDNA-IRF-7A; lanes 7 to
9, pcLMP-1 plus IRF-7A, IRF-7C, and IRF-7DN expression plasmids,
respectively. Specific protection of Tap-2 and GAPDH RNAs and
undigested probes is indicated. Bottom panel, short exposure for
GAPDH-protected areas. (B) Relative Tap-2 levels from panel A.
Data were obtained by normalizing Tap-2 RNA levels to GAPDH
RNA levels with the use of a PhosphorImager. The column numbers
match the lanes in panel A.
FIG. 5. IRF-7 and LMP-1 coactivate endogenous Tap-2. (A) RPA
was performed with Tap-2 and GAPDH probes. Lane 1, RNA from
the T-2 cell line; lanes 2 to 5, RNAs from transfected Akata cells.
Transfections: lane 2, pcDNA3; lane 3, pcLMP-1; lane 4, pcDNA-IRF-
7A; lane 5, pcLMP-1 plus IRF-7A. Specific protections and undigested
probes are shown. Bottom panel, short exposure for GAPDH-pro-
tected areas. A representative experiment is shown. (B) Relative Tap-2
levels from panel A. Data were obtained by normalizing Tap-2 RNA
levels to GAPDH RNA levels with the use of a PhosphorImager. The
column numbers match the lanes in panel A. (C) Western blot analysis
of transfected cells with various antibodies. The identity of proteins is
indicated.
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LMP-1 could activate the endogenous Tap-2 gene (lane 3).
These data are in agreement with the facts that IRF-7A is a
major form of IRF-7 and that LMP-1 primarily stimulates the
expression of IRF-7A (66, 67).
To dissect the domain requirement of LMP-1 for the activation
of Tap-2, LMP-1 mutants were tested along with IRF-7A for their
ability to increase endogenous Tap-2 RNA in Akata cells. Cur-
rently, two major functional domains of LMP-1 have been dis-
sected, namely, CTAR-1 and CTAR-2. These two domains can
activate different signaling molecules (16, 29). As shown in Fig. 6
(lanes 9 to 12), full-length LMP-1 is most efficient for the induc-
tion of Tap-2 with IRF-7A (lane 2).
LMP-1 enhances phosphorylation and nuclear transloca-
tion of IRF-7. In order to understand the mechanism whereby
LMP-1 and IRF-7 coactivate Tap-2, we examined whether
LMP-1 regulates IRF-7 in a posttranslational manner. Because
LMP-1 is known to activate several important cellular mole-
cules through phosphorylation and IRF-7 may be phosphory-
lated upon viral infection (24, 61), whether LMP-1 induces the
phosphorylation of IRF-7 was examined. Cells transfected with
IRF-7 or LMP-1 plus IRF-7 were labeled with [32P]orthophos-
phate, and cell lysates were used for immunoprecipitation with
IRF-7 antiserum. The immunoprecipitates were analyzed by
SDS-PAGE and transferred onto a membrane, which was an-
alyzed by autoradiography as well as by Western blot. As
shown in Fig. 7A, IRF-7 itself is a phosphoprotein (lanes 1 and
3); however, LMP-1 could enhance the phosphorylation status
of IRF-7 (lanes 2 and 4).
Next, whether endogenous LMP-1 can enhance the phos-
phorylation of IRF-7 was examined. DG75 is an EBV-negative
BL cell line with moderate levels of endogenous IRF-7, and
Jijoye is an EBV-positive type III latency cell line that ex-
presses LMP-1. These cells were labeled, and phosphorylation
of IRF-7 in these cells was examined. Because the endogenous
IRF-7 level in DG75 cells was lower than in Jijoye cells, more
DG75 cell lysate was used for immunoprecipitation. As shown
in Fig. 7A, the IRF-7 in DG75 cells was less phosphorylated
than the IRF-7 in Jijoye cells (lanes 5 and 6). Also, highly
phosphorylated IRF-7 was readily detectable in other type III
cells, such as B958/CBC and X50-7 (data not shown).
Since viral infection may facilitate the nuclear translocation
of IRF-7 (1, 61), whether LMP-1 expression affects the sub-
cellular localization of IRF-7 was examined in EBV-negative
293T cells. As shown in Fig. 7B, most of the IRF-7 when
expressed alone was localized in the cytoplasm; however, when
LMP-1 was present, most of the IRF-7 localized in the nucleus
with a punctate appearance. In type III cells, endogenous
IRF-7 is also mainly localized in the nucleus (data not shown).
Therefore, LMP-1 augments the phosphorylation and nuclear
translocation of IRF-7.
DISCUSSION
The signal transduction pathway of LMP-1 has been exten-
sively studied. The involvement of tumor necrosis factor re-
ceptor-associated factors and NF-kB in the immediate steps of
the signal transduction pathway has been established conclu-
sively (9, 17, 25, 26, 28, 50). While induction of some genes by
LMP-1 may result from the direct activation of NF-kB, other
genes may need a secondary mediator(s). Here we have shown
that the induction of Tap-2 requires IRF-7 as a secondary
mediator. First, Tap-2 expression is associated with both IRF-7
and LMP-1 expression (Fig. 1) (46, 66). Second, LMP-1 in-
duces Tap-2 expression in DG75, BJAB, and BL41 cells, in
which IRF-7 can be stimulated (Fig. 4) (46) (data not shown).
Also, ectopic expression of IRF-7 enhances the induction of
Tap-2 by LMP-1 in DG75 cells (Fig. 4). Third, LMP-1 could
not induce Tap-2 in Akata cells, in which IRF-7 could not be
induced by LMP-1. However, addition of ectopic IRF-7, which
artificially restores the defect, could activate the expression of
Tap-2 in Akata cells (Fig. 5). Fourth, the Tap-2 promoter
construct could be activated by IRF-7 and further enhanced by
LMP-1 specifically. Also, the activation of the Tap-2 promoter
was dependent on the intact ISRE sequence (Fig. 3). Fifth,
FIG. 6. IRF-7A and full-length LMP-1 are required for the efficient
activation of endogenous Tap-2. (A) RPA was performed with Tap-2
and GAPDH probes. Lanes 1 and 2, yeast RNA and RNA from the
T-2 cell line; lanes 3 to 7, RNAs from transfected Akata cells. Plasmid
pcLMP-1 was transfected with pcDNA-IRF-7A (lane 3), IRF-7B (lane
4), IRF-7C (lane 5), IRF-7DN (lane 6), IRF-2 (lane 7), or pcDNA3
(lane 8). Lanes 9 to 12, pcDNA-IRF-7A was transfected with pcDNA3
(lane 9), full-length pcLMP-1 (lane 10), LMP CTAR-1 (lane 11), or
CTAR-2 (lane 12). Bottom panel for lanes 9 to 12, short exposure for
GAPDH-protected area. Specific protections are shown. A represen-
tative experiment is shown. (B) Relative Tap-2 levels from panel A.
Data were obtained by normalizing Tap-2 RNA levels to GAPDH
RNA levels with the use of a PhosphorImager. The column numbers
match the lanes in panel A.
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IRF-7 could bind specifically to the ISRE in the Tap-2 pro-
moter in vitro and to the Tap-2 promoter under physiological
conditions in vivo (Fig. 2). Sixth and finally, LMP-1 facilitates
the phosphorylation and nuclear translocation of IRF-7 (Fig. 7).
It is apparent that IRF-7 is the most relevant IRF member
for the activation of Tap-2 by LMP-1. First, both IRF-7 and
IRF-2 are associated with EBV type III latency, in which levels
of Tap-2 are high. IRF-2 could also bind to the Tap-2 ISRE, as
determined by EMSA (data not shown). However, neither
IRF-2 nor LMP-1 plus IRF-2 could activate Tap-2 expression.
Also, LMP-1 cannot induce the expression of IRF-2 (66). Sec-
ond, LMP-1 could specifically enhance the activation of the
Tap-2 promoter by IRF-7 but not by IRF-1, although IRF-1
can activate the Tap-2 promoter reporter (Fig. 3C). Third,
other IRFs tested, such as IRF-1, IRF-3, and ICSBP, are not
associated with type III latency (34, 66, 67). Fourth and finally,
LMP-1 regulates IRF-7 in a posttranslational manner (Fig. 7).
Therefore, LMP-1 has an intimate relationship with both the
expression and activation of IRF-7.
Considering all the existing data, we propose an LMP-1-
triggered signal transduction pathway that leads to stimulation
of expression of IRF-7. LMP-1 further activates IRF-7 by
phosphorylation and nuclear translocation of the protein. Fi-
nally, activated IRF-7 mediates the activation of the Tap-2
gene (Fig. 8).
The domain analysis of activation of Tap-2 by IRF-7 showed
that full-length IRF-7A is required both for activation of the
Tap-2 promoter construct and for the increase in endogenous
Tap-2 RNA (Fig. 3 and 6). These data suggest that the IRF-7A
activation domain, at least in the B-cell lines tested, is located
in the C terminus beyond aa 227, because IRF-7B, which lacks
aa 227 to 255 in IRF-7A, could not activate Tap-2. This result
FIG. 7. LMP-1 facilitates the phosphorylation and nuclear translocation of IRF-7. (A) LMP-1 facilitates the phosphorylation of IRF-7. 293T
cells were transfected with IRF-7A with (lanes 2 and 4) or without (lanes 1 and 3) LMP-1 expression plasmid. At 24 h after transfection, cells were
labeled with [32P]orthophosphate, immunoprecipitates were separated in SDS-PAGE and transferred to a membrane, and Western blotting with
IRF-7 antibody was done after autoradiography for detection of phospho-IRF-7. Lanes 5 and 6, DG75 and Jijoye cells were labeled with
[32P]orthophosphate, respectively. More DG75 cell lysate was needed for immunoprecipitation in order to get equal amounts of total IRF-7. (B)
LMP-1 facilitates the nuclear translocation of IRF-7. 293T cells were transfected with EGFP-IRF-7A with or without the LMP-1 expression
plasmid. The subcellular localization of IRF-7 was examined 24 h after transfection. Several cells were not transfected with the EGFP-IRF-7A
plasmid. Arrows indicate corresponding cells. Magnification, 3400.
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seems to contradict a previously reported activation domain
(corresponding to aa 107 to 224 of IRF-7A) obtained in the
L929 mouse fibroblast line (1). The different cell lines that
were used for the study may contribute to this discrepancy. In
support of such a notion, IRF-7B could efficiently activate the
Tap-2 promoter construct in FaDuHyg, an epithelial cell line
(data not shown). However, considering that IRF-7 is primarily
a lymphoid factor, a conclusion based on B cells may be more
relevant to its biological function.
IRF-7 appears to be a secondary mediator for the repression
of the EBV latency promoter (Qp) by LMP-1 (66). In this
paper, we have shown that IRF-7 is a secondary mediator for
Tap-2 activation. The domain requirements of IRF-7 for these
two biological effects are quite different. For Qp repression,
the N-terminal DNA-binding domain is sufficient (67); how-
ever for Tap-2 activation, both the N- and C-terminal domains
of IRF-7 are required (Fig. 3 to 6). Whether IRF-7 is involved
in the induction of more LMP-1-regulated genes needs to be
addressed. Since HLA 1, Tap-1, and Tap-2 are often induced
simultaneously for antigen processing (e.g., by treatment with
IFN-a, IFN-g, or lipopolysaccharide), it is tempting to specu-
late that IRF-7 may also be involved in the regulation of the
Tap-1 and HLA I genes, both of which have been shown to be
regulated by IRF-1 (39, 62).
What advantage does EBV gain by inducing Tap-2 and other
HLA I-related genes? Type III EBV latency, an LMP-1-ex-
pressing latency state, is established transiently in primary in-
fection of human B cells in vivo (reviewed in references 19 and
44). Type III cells have enhanced growth, survival, and invasive
potential, which allow the EBV-infected cells to proliferate
quickly, thereby putting the human host at risk. This rapid
proliferative process is checked after the development of EBV-
specific primary cytotoxic T lymphocytes (CTL), which elimi-
nate these type III latency cells because of the activation of
Tap-2 and other HLA I-related genes by LMP-1, and ensure
the safety of the host. In X-linked immunoproliferative dis-
ease, in which T-cell activation is defective (51), EBV infection
is lethal. Interestingly, EBV in the normal host still survives the
CTL attack by establishing a type I-like latency state, in which
LMP-1 is not expressed (6, 30, 31, 40, 56). This type I-like
latency can escape host immune surveillance, which ensures
the survival of the virus. Because the whole process may ensure
the survival both of the host and of the virus, a life-long coex-
istence may thus be maintained between the human host and
EBV. In support of such a notion, the LMP-1-positive immu-
noblastic B-cell lymphomas of the immunosuppressed are
highly susceptible to recovered patients’ cytolytic T cells or to
adoptive CTL therapy (7, 8, 38, 45).
In summary, our data provide direct evidence that IRF-7 is
involved in regulation of a crucial immune system gene and is
a secondary mediator for the LMP-1 viral protein in modulat-
ing the normal functions of the immune and inflammatory
responses.
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